Factor VII TRIZ Cases
- Polymer-VWF Conjugates for Prolonged Protein Half-Life
Polymer-VWF conjugates extend circulating protein half-life, reducing dosing frequency for bleeding disorder treatment.
- Modified FVIII VWF Fusion Proteins Prolonged Half-Life
Fusion of half-life enhancing polypeptides to coagulation factors extends plasma circulation time, reducing infusion frequency for hemophilia treatment.
- ADAMTS13 Polypeptide Substrate Autofluorescence Reduction
Mutated ADAMTS13 polypeptide substrate eliminates autofluorescence noise from FRETS-VWF73, delivering linear calibration curves for accurate TTP diagnosis.
- Hyaluronic Acid Gelatine Haemostatic Sponge Swelling Control
A haemostatic composition combines gelatine with hyaluronic acid to enhance bleeding control and absorption properties.
- Fc-Fused FVIII Protein for Hemophilia A Prophylaxis
Efanesoctocog alfa extends factor VIII half-life via Fc fusion, reducing bleeding episodes and patient burden.
- Growth Factor Binding Peptides for Wound Healing
Transglutaminase-reactive peptide carriers localize growth factors to reduce cancer risk while enhancing bone repair.
- Multimodal Resin Purification of Factor VIII
A multimodal resin captures Factor VIII via hydrophobic and electrostatic interactions for single-step purification.
- Composite TREs for Compact AAV Vectors
Composite transcription regulatory elements combine hAAT and AMBP sequences to drive high expression levels within compact AAV vectors.
- RNA-Guided Endonuclease Corrects F8 Gene Inversions
RNA-guided endonucleases correct large F8 gene inversions that conventional PCR cannot amplify, enabling accurate hemophilia A model generation.
- Isothiocyanate Factor IX Polymer Conjugates
Isothiocyanate linkages replace oxidizers, preventing polymer degradation while extending plasma half-life.
- Variant Serum Albumin FcRn Binding for Half-Life Extension
Modified serum albumin sequences adjust pH-dependent FcRn interactions to reduce clearance and lower dosing frequency.
- NE-AAV Vectors for Sustained Liver Gene Therapy
Modified no-end AAV genomes maintain transgene expression in growing livers, avoiding dilution from cell division and pre-existing antibodies.
- Oral Tolerance Agents for Hemophilia Protein Replacement
Chloroplast-expressed factor IX administered orally suppresses inhibitor formation and prevents anaphylactic reactions during protein replacement therapy.
- Activated Factor V Mutations for Hemophilia Coagulation
Mutated factor V resists degradation to improve hemostasis despite phenotype variability.
- Arginine-Formulated Fibrinogen for Rapid Reconstitution
Arginine-enhanced fibrinogen dissolves rapidly at room temperature, eliminating cold chain logistics and protein degradation risks.
- Single Chain FVIII Polypeptide Expression for Extended Half-Life
Fusing Factor VIII to albumin-binding moieties extends serum half-life, reducing injection frequency for hemophilia A treatment.
- Modified MSC Transplantation for Hemophilia A Treatment
Transplanted modified mesenchymal stem cells secrete Factor VIII, avoiding inhibitory antibodies and lifelong infusions.
- Recombinant VWF Proteins for Prolonged Half-Life
Site-specific mutations in recombinant von Willebrand Factor reduce clearance receptor binding to prolong half-life and sustain bleeding control.
- Viral Vector Purification via Transgene Protein Capture
Sequential chromatography steps remove transgene protein contaminants, ensuring viral vector purity for safe gene therapy administration.
- Modified VWF D' Domain Mutations for Factor VIII Binding
Specific D' domain mutations in modified von Willebrand Factor increase Factor VIII binding affinity, stabilizing the complex and prolonging half-life.
- CAR-Engineered Tregs for Hemophilia A Inhibitor Suppression
CAR-expressing Tregs suppress anti-factor VIII inhibitors, reducing treatment complexity and cost compared to conventional protocols.
- Proteolytically Cleavable Linkers for Fusion Protein Activity
Cleavable linkers separate coagulation factors from half-life enhancers, restoring high molar specific activity and reducing thrombotic complications.
- Lesion-Targeted Fusion Polypeptides for Immune Modulation
Fusion polypeptides combine immunomodulators with collagen-binding aptamers to deliver therapeutic agents directly to tissue lesions.
- Dual Vector Co-Expression of FVIII and Truncated vWF-Fc
Co-expressing Factor VIII with mutated vWF-Fc via a single plasmid ensures consistent 1:1 ratios, preventing purification bottlenecks from excess vWF.